Novo licenses China-based biotech's weight-loss drug candidate for up to $2 billion
(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United Laboratories International's weight-loss drug candidate in a deal worth up to ...
Yahoo Finance22d
Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth
HELLERUP, Denmark, LONDON and KEELE, England, March 3, 2025 /PRNewswire/ -- Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo ...
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investo ...